Metabolisches Syndrom und kardiovaskuläre Komplikationen

Astrup A, Grunwald GK, Melanson EL et al. (2000) The role of low-fat diets in body weight control: a meta-analysis of ad libitum dietary intervention studies. Int J Obes 24: 1545–1552 Canner PL, Furberg CD, Terrin ML, McGovern ME (2005) Benefits of niacin by glycemic status in patients with healed myocardial infarction (from the Coronary Drug Project). Am J Cardiol 95: 254–257 Chiasson JL, Josse RG, Gomis R et al. (2003) Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial. JAMA 290: 486–494 DeFronzo RA, Ratner RE, Han J et al. (2005) Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care 28: 1092–1100 Dormandy JA, Charbonnel B, Eckland DJA et al. (2005) Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinial Trial in macroVascular Events): a randomized controlled trial. Lancet 266: 1279–1289 Grundy SM, Cleeman JI, Daniels SR et al. (2005) Diagnosis and management of the metabolic syndrome. An American Heart Association/National Heart, Lund, and Blood Institute Scientific Statement. Executive summary. Circulation 112: 2735–2752 Hotamisligl GS (2000) Molecular mechanisms of insulin resistance and the role of the adipocyte. IJO 24: S23–S27 Isomaa B, Lahti K, Almgren P et al. (2001) Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 24: 683–689 Keech A, Simes RJ, Barter P et al. (2005) Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes (the FIELD study): randomised controlled trial. Lancet 366: 1849–1861 Knowler WC, Barret-Connor E, Fowler SE et al. (2002) Reduction in the incidence of type 2 diabetes with lifestyle intervenion and metformin. NEJM 346: 393–403 Marchioli R, Barzi F, Bomba et al. (2002) Early protection against sudden death by n-3 polyunsaturated fatty acids after myocardial infarction. Time-course analysis of the results of the Gruppo Italiano per lo Studio della Sopravivenza nell’Infarto Miocardio (GISSI-Prenzione). Circulation 105: 1897–1903 Mehnert H (1984) Behandlung mit Biguaniden. In: Mehnert H, Schöffling K (Hrsg) Diabetologie in Klinik und Praxis. Thieme, Stuttgart, S 240–250 Peirce NS, Stubbs TA, Macdonald IA, Tattersall RB (1998) The effect of sibutramine and weight reduction on insulin sensitivity in obese type 2 diabetics. Int J Obes 22: P669 Pischon T, Girman CJ, Hotamisligil GS et al. (2004) Plasma adiponectin levels and risk of myocardial infarction in men. JAMA 291: 1730–1737 Reilly MP, Lehrke M, Wolfe ML et al. (2005) Resistin is an inflammatory marker of atherosclerosis in humans. Circulation 111: 932–939 Ridker PM, Rifai N, Rose L et al. (2002) Comparison of c-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med 347: 1557–1565 Robins SJ, Elam MB, Rubins HB et al. (2003) Insulin resistance and cardiovascular events with low HDL cholesterol. The Veterans Affairs HDL Intervention trial (VA-HIT). Diabetes Care 26: 1513–1517 Sattar N, Gaw A, Scherbakova O et al. (2003) Metabolic syndrome with and without c-reactive protein as a predictor of coronary heart disease and diabetes in the West of Scotland Coronary Preventions Study. Circulation 108: 414–419 Schupp M, Janke J, Clasen R et al. (2004) Angiotensin type 1 receptor blockers induce peroxisome proliferator-activated receptor-gamma activity. Circulation 109: 2054–2057 Sprecher DL, Pearce GL (2000) How deadly is the „deadly quartet“? J Am Coll Caridiol 36: 1159–1165 Togerson JS, Boldrin MN, Hauptmann J, Sjöström L (2004) XENical in the Prevention of Diabetes in the Obese Subjects (XENDOS) Study. A randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese subjects. Diabetes Care 27: 155–161 Tuomilehto J for the DECODE study group on behalf of the European Diabetes Epidemiology Group (1999) Glucose tolerance and mortality: comparison of WHO and American Diabetes Association diagnostic criteria. Lancet 354: 617–621 Tuomilehto J, Lindström J, Eriksson JG et al. (2001) Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 244: 1343–1350 van Gaal L, Rissanen AM, Scheen A et al. (2005) Effects fo the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Lancet 365: 1389–1397 Vesby B, Uusitupa M, Hermansen K et al. (2001) Substituting dietary saturated for unsaturated fat impairs insulin sensitivity in healthy men and women: The KANWU study. Diabetologia 44: 312–319 Wirth A (2000) Adipositas: Epidemiologie, Ätiologie, Folgekrankheiten und Therapie, 2. überarbeitete u. erweiterte Aufl. Springer, Berlin Heidelberg New York Tokyo Wirth A, Gohlke H (2005) Rolle des Körpergewichts für die Prävention der koronaren Herzkrankheit. Z Kardiol 94 [Suppl 3]: III/22–III29